CA3075482A1 - Methods and compositions for treating chronic lung diseases - Google Patents
Methods and compositions for treating chronic lung diseases Download PDFInfo
- Publication number
- CA3075482A1 CA3075482A1 CA3075482A CA3075482A CA3075482A1 CA 3075482 A1 CA3075482 A1 CA 3075482A1 CA 3075482 A CA3075482 A CA 3075482A CA 3075482 A CA3075482 A CA 3075482A CA 3075482 A1 CA3075482 A1 CA 3075482A1
- Authority
- CA
- Canada
- Prior art keywords
- igf
- months
- weeks
- analog
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1754—Insulin-like growth factor binding proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557113P | 2017-09-11 | 2017-09-11 | |
| US62/557,113 | 2017-09-11 | ||
| PCT/US2018/050427 WO2019051474A1 (en) | 2017-09-11 | 2018-09-11 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3075482A1 true CA3075482A1 (en) | 2019-03-14 |
Family
ID=63794620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075482A Pending CA3075482A1 (en) | 2017-09-11 | 2018-09-11 | Methods and compositions for treating chronic lung diseases |
Country Status (25)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3681602B1 (en) | 2017-09-11 | 2026-04-15 | Oak Hill Bio Limited | Compositions for reducing the incidence of bpd |
| KR20230113287A (ko) * | 2020-10-19 | 2023-07-28 | 오크 힐 바이오 리미티드 | 신생아에 사용하기에 적합한 조성물 |
| CA3248280A1 (en) * | 2022-05-04 | 2023-11-09 | Oak Hill Bio Limited | POLYTHERAPY FOR PREMATURE INFANTS |
| WO2023242440A1 (en) * | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Treament of lungs in infants |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| ATE90690T1 (de) | 1987-04-06 | 1993-07-15 | Celtrix Pharma | Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung. |
| DK131988A (da) | 1988-03-11 | 1989-09-12 | Erasmus University | Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur |
| US5258287A (en) | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
| ATE132164T1 (de) | 1988-04-12 | 1996-01-15 | Amgen Boulder Inc | Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors |
| GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
| IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
| EP0639981A4 (en) | 1992-05-08 | 1995-06-28 | Univ Jefferson | ANALOGS OF THE IGF FACTOR (01/18/94). |
| US5563046A (en) | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
| US5789547A (en) | 1995-06-07 | 1998-08-04 | Celtrix Pharmaceuticals, Inc. | Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding |
| US5783556A (en) | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| EP0956041A1 (en) | 1996-09-16 | 1999-11-17 | Dalhousie University | Use of igf-i for the treatment of polycystic kidney disease and related indications |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US20020028764A1 (en) | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
| CA2429615C (en) | 2000-11-28 | 2016-07-12 | Children's Medical Center Corporation | Determination of risk and treatment of complications of prematurity |
| WO2004113382A1 (en) | 2003-06-13 | 2004-12-29 | Insmed, Inc. | Recombinant igf expression systems |
| CA2899824A1 (en) | 2004-12-24 | 2006-06-29 | Insmed, Inc. | Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture |
| WO2008130315A1 (en) * | 2007-04-18 | 2008-10-30 | Premacure Ab | Method and product for treatment and/or prevention of complications of prematurity |
| RU2558821C2 (ru) | 2009-11-17 | 2015-08-10 | Ипсен Фарма С.А.С. | ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1 |
| US9168289B2 (en) | 2011-02-01 | 2015-10-27 | Mor Research Applications Ltd. | Method of treatment of small for gestational age infants under two years of age |
| CA2897062A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Lyophilization process |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| EP3681602B1 (en) | 2017-09-11 | 2026-04-15 | Oak Hill Bio Limited | Compositions for reducing the incidence of bpd |
-
2018
- 2018-09-11 EP EP18783187.0A patent/EP3681602B1/en active Active
- 2018-09-11 EP EP25211426.9A patent/EP4663184A3/en active Pending
- 2018-09-11 UA UAA202002323A patent/UA128690C2/uk unknown
- 2018-09-11 US US16/127,988 patent/US20190151411A1/en not_active Abandoned
- 2018-09-11 BR BR112020004760-0A patent/BR112020004760A2/pt unknown
- 2018-09-11 PT PT187831870T patent/PT3681602T/pt unknown
- 2018-09-11 KR KR1020207009049A patent/KR20200097679A/ko not_active Ceased
- 2018-09-11 CA CA3075482A patent/CA3075482A1/en active Pending
- 2018-09-11 IL IL273174A patent/IL273174B2/en unknown
- 2018-09-11 EA EA202090705A patent/EA202090705A1/ru unknown
- 2018-09-11 AU AU2018328827A patent/AU2018328827B2/en active Active
- 2018-09-11 ES ES18783187T patent/ES3075637T3/es active Active
- 2018-09-11 LT LTEPPCT/US2018/050427T patent/LT3681602T/lt unknown
- 2018-09-11 PE PE2020000320A patent/PE20201166A1/es unknown
- 2018-09-11 EP EP26172376.1A patent/EP4748372A3/en active Pending
- 2018-09-11 WO PCT/US2018/050427 patent/WO2019051474A1/en not_active Ceased
- 2018-09-11 MX MX2020002744A patent/MX421623B/es unknown
- 2018-09-11 DK DK18783187.0T patent/DK3681602T3/da active
- 2018-09-11 CN CN201880058512.XA patent/CN111432881A/zh active Pending
- 2018-09-11 MY MYPI2020001266A patent/MY204825A/en unknown
- 2018-09-11 JP JP2020514518A patent/JP7819893B2/ja active Active
- 2018-09-11 SG SG11202002088TA patent/SG11202002088TA/en unknown
-
2020
- 2020-03-09 CL CL2020000597A patent/CL2020000597A1/es unknown
- 2020-03-11 PH PH12020500489A patent/PH12020500489A1/en unknown
- 2020-03-12 ZA ZA2020/01568A patent/ZA202001568B/en unknown
- 2020-04-07 CO CONC2020/0004244A patent/CO2020004244A2/es unknown
- 2020-09-08 EC ECSENADI202055797A patent/ECSP20055797A/es unknown
-
2021
- 2021-05-11 US US17/317,152 patent/US12678482B2/en active Active
-
2023
- 2023-08-01 JP JP2023125304A patent/JP2023145646A/ja active Pending
-
2024
- 2024-08-30 US US18/821,397 patent/US20240415927A1/en active Pending
- 2024-10-24 AU AU2024227601A patent/AU2024227601B2/en active Active
-
2025
- 2025-05-23 JP JP2025086115A patent/JP2025114869A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024227601B2 (en) | Methods and compositions for treating chronic lung diseases | |
| TWI912393B (zh) | 適用於新生兒的組成物 | |
| US9463222B2 (en) | Methods for treatment of complications of prematurity comprising administration of IGF-I and IGFBP-3 | |
| AU2002239560A1 (en) | Determination of risk and treatment of complications of prematurity | |
| HK40033881A (en) | Methods and compositions for treating chronic lung diseases | |
| EA044079B1 (ru) | Способы и композиции, предназначенные для лечения хронических заболеваний легких | |
| EA049095B1 (ru) | Композиции, подходящие для применения у новорожденных | |
| HK40099225A (en) | Compositions suitable for use in neonates | |
| HK40099225B (en) | Compositions suitable for use in neonates | |
| KR20250169179A (ko) | 재조합 인간 계면활성제 단백질 d(rhsp-d)의 투여에 의해 조기 미숙아를 치료하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230908 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250213 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250611 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250612 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250812 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250812 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20260507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260507 |